The novel coronavirus disease 2019 (COVID-19) is a respiratory infection that has received much attention due to its rapid expansion . Currently, it has been revealed that patients with underlying disease, especially those with kidney disease are more prone to develop complications . Some studies associate kidney transplantation as a risk factor for COVID-19 progression; however, epidemiologic data that demonstrate this are amazingly rare . Considering the importance of the topic, we report on six kidney transplant recipients (median age 47 [41-55] ) with confirmed or clinically suspected COVID-19 . The most common admission presentations were fever (83.3 %), dyspnea, and myalgia . At baseline, immunosuppressive therapy was ceased, prednisolone dose was increased, and all patients received antiviral treatment including hydroxychloroquine and umifenovir . After a median follow-up of 11.5 days from admission, six patients (100 %) developed acute kidney injury (AKI), 50% required intensive care unit (ICU) admission, and two patients (33.3 %) deceased as a result of deterioration in respiratory status . Overall, these findings demonstrate that respiratory involvement may be a risk indicator of in-hospital mortality in kidney recipients with COVID-19. In addition, AKI development in kidney recipients with COVID-19 is of utmost importance given the higher AKI occurrence in these patients compared with others . Therefore, more intensive attention should be paid to kidney transplant recipients with COVID-19.
Index: AKI, COVID-19, Immunosuppression, Kidney transplant